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Abstract
The enteric nervous system (ENS), also known as second brain, innervates our 
gastrointestinal tract controlling its functions, such as motility, fluid secretion, 
nutrient absorption, and even involvement in the control of immunity and inflam-
matory processes. In the gut, the gliocytes are known as enteric glial cells (EGCs). 
Enteric glial cells form a network that permeates the entire gut. Enteric glia express 
the cell surface hemichannel of connexin-43 (Cx43) necessary for the propagation 
of Ca2 + responses, necessary to maintain their functions. In this chapter, besides 
the development of ENS and its glial cells and the similarities with the astrocytes in 
the central nervous system, we approached the important role of the glial network 
in the control of gut homeostasis, in the interaction with the immune system, and 
its participation in pathological conditions. EGCs are even capable of replacing lost 
neurons. Thus the enteric glia is a multifunctional cell, which through its multiple 
interactions maintains the integrity of the ENS allowing it to be resistant to the 
different and constant aggressions suffered by the digestive system.
Keywords: enteric glial cells, glial network, gut homeostasis, gut inflammation, 
enteric neurodegeneration
1. Introduction
The enteric nervous system (ENS), also known as second brain, innervates our 
gastrointestinal tract from the esophagus to the rectum including the pancreas and 
gallbladder, controlling its functions. The ENS develops from the neural crest cells 
(NCCs). At the vagal (at the level of somites 1–7) and sacral (posterior to somite 
28) regions of the anteroposterior axis, some of NCCs, the enteric neural crest 
cells (ENCCs), enter the rudimental digestive system, proliferate, and migrate to 
colonize the primitive gut [1].
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The differentiation of enteric neurons starts prior to the enteric glial cells 
(EGCs). Behind the migratory wavefront, the first neurons arise at E10–E10.5 in 
the foregut level. Genes of multipotent ENCCs, such as Sox10, FoxD3, and P75, 
are downregulated, and cells begin to express specific neuronal markers, such as 
βIIItubulin, RET, HuC/D, and peripherin. Subsequently, at E11.5, the glial dif-
ferentiation takes place, and the ENCCs downregulate RET expression, while 
markers such as Sox10, FoxD3, and P75 continue to be expressed. Additionally, 
other genes that are known to be specifically expressed in EGCs appear, including 
S100B, glial fibrillary acidic protein (GFAP), and proteolipid protein 1 (PLP1). The 
development of the mature ENS network is not complete at birth, and the neuronal 
differentiation is extended to up to 2 weeks after birth (for a detailed description of 
enteric neurons and glial cells development, [1]).
Initially, ENCCs migrate as intersections of narrow chains of cells. Later on, as devel-
opment progresses further, these cells aggregate into numerous ganglia that are con-
nected by neuronal projections and EGCs (Figure 1). The role of bone morphogenetic 
proteins (BMPs)-2 and (BMPs)-4 in the neural cell adhesion molecule (NCAM) regula-
tion that are differentially expressed by the cells to form these ganglion-like aggregates 
is already known [2–6]. The growth factor endothelin3 (EDN3) is important to keep 
ENS progenitors cells in a proliferative state. It inhibits reversibly the commitment and 
differentiation of these cells, and in this way it is involved in the correct migration of 
enteric neural crest cells to colonize the gut [4]. Lack of EDN3 leads to aganglionosis 
of the distal bowel [5]. It is well known that thyroid hormone 3,5,3′-triiodothyronine 
(T3) plays an important role in CNS development, and also appears to play a role in the 
development of the ENS. In vitro, T3 inhibits cell proliferation and stimulated neurite 
growth of differentiating murine enteric neural crest cells [6]. But, interestingly, this 
work also showed that spheres of neonate mice ENS progenitor cells increased EDN3 
expression by more than 3-fold after T3 treatment, demonstrating a likely crosstalk 
between these signalling pathways [6]. In the adult mammalian, the ENS is organized 
into the myenteric and submucosal ganglionated plexuses composed of neurons and 
EGCs and non-ganglionated plexuses, composed of EGCs that tightly follow neuronal 
projections that reach all regions of the intestines, including the mucosa. The myenteric 
plexus (or Auerbach’s plexus) is located between the outer longitudinal and circular 
muscle layers, and the submucosal plexus (or Meissner’s plexus) lies in the submucosal 
region (between the mucosa and the muscular layers) [1].
Figure 1. 
(A) Transverse section of mouse embryo gut at embryonic day (E)14.5 stained for the glial marker P75. The 
cells are not yet organized in ganglia. (B) Longitudinal muscle with the adherent myenteric plexus (LMMP) of 
adult mouse colon. The enteric glial network is evidenced by GFAP staining. Scale bars: 50 μm.
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EGCs are distributed across all layers of the intestine and are currently clas-
sified into four different subtypes based on their location and morphology. 
Intraganglionic EGCs (type I) present numerous short and irregular processes 
and resemble the protoplasmic astrocytes of the central nervous system (CNS); 
the interganglionic EGCs surround neuronal projections that connect multiple 
ganglia (type II); the mucosal EGCs (type III) are found around neuronal projec-
tions located in the mucosal region and present long and branched processes; and 
intramuscular EGCs (type IV) are bipolar and elongated and accompany the nerve 
fibers that cross the muscle layers [7, 8]. In fact, their wide distribution reflects on 
their performance in different physiological aspects of the gastrointestinal (GI) 
tract. Indeed, EGCs were shown to participate in the homeostasis of the intestinal 
epithelial barrier (IEB), to coordinate the GI motility taking part in neurotransmis-
sion, and also to modulate inflammation and immune responses.
2.  Enteric glia: a unique glial cell type - similarities and differences with 
astrocytes
In the first studies about enteric glia, the ultrastructure of the glial cell of myen-
teric plexus was described as a small cell body with many processes. It was sug-
gested that the star-like morphology, as well as the anatomical relation to neurons, 
resembles astrocytes from the CNS rather than Schwann cells [9]. Jessen et al. [10] 
showed that intraganglionic EGCs express the characteristic marker of an astrocytic 
cell, glial fibrillary acidic protein (GFAP), corroborating the assumption that ENS 
glial cells are analogous to CNS astrocytes [11, 12], although they have different 
embryological origins.
EGCs and astrocytes exhibit molecular similarities in their electrophysiologi-
cal properties [13] and express the same group of proteins, including the GFAP 
[14], and the S100β-linked binding pathway [15]. However, not all properties of 
the EGCs are similar to astrocytes. They have different embryological origins, 
for example, astrocytes coming from neuroepithelium and EGCs from neural 
crest. During the embryonic stages, neuregulin signaling via the ErbB3 receptor is 
critical for the development of the EGCs, whereas astrocytes do not require such 
signaling [16]. Unlike astrocytes, EGCs do not express the protein of the aldehyde 
dehydrogenase 1 L1 (Aldh1L1) [8] but express the transcription factor Sox10 [17] 
and the protein PLP1, implicated in myelin production and most commonly found 
in oligodendrocytes and Schwann cells. In fact genic signature of EGCs seems to be 
more similar to that of oligodendrocytes and Schwann cells than to astrocytes [18].
Similar to astrocytes, EGCs interact with and modulate the performance of differ-
ent cell types, as we will see throughout this chapter. In addition to interacting with 
neurons, EGCs establish multidirectional communication with other cell types, such as 
intestinal mucosal epithelial, muscle, mesenchymal, and immune cells [19].
3.  Formation of the gut glial network and the communication through 
connexin-43 (Cx43) hemichannels
Yet during development, EGCs begin to form a network of interconnected cells 
that permeate the entire gut (Figure 1).
Gabella noted that a striking feature of EGC is the presence of numerous 
intramembrane particles on its surface [20], and a small part are gap junctions. 
These intramembrane particles are believed to be hemichannels. It has recently 
been found that, as astrocytes, enteric glial hemichannels are connexin-43 (Cx43) 
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compounds [21]. Cx43 hemichannels are Ca2+−permeable channels that are also 
controlled by Ca2+ [21].
Like astrocytes, activated EGCs have excitability mediated by transitory intra-
cellular Ca2+ elevations, considered central to many functions. Most of the enteric 
glial receptors for neuroactive compounds are G-protein-coupled receptors, and 
most of these leads to activation of downstream effectors that elevate intracellular 
Ca2+. As mentioned by Gulbransen in his book (2014, p. 28) [22], being able to 
detect the increase in Ca2+ levels was essential to establish that neuron-glial com-
munication occurs in ENS and to identify involved mediators. The study realized by 
McClain et al. [21] also showed the role of Cx43 hemichannels in the propagation 
of “calcium waves” through the enteric glia network and in the regulation of GI 
motility [21]. It was shown that glial “calcium waves” activated by extracellular 
ATP or ADP were disrupted by glial specific loss of Cx43 and result in aberrant ENS 
network activity and GI dysmotility.
Cx43 expression in EGCs is also related to inflammatory process. Neuronal loss 
is one of the intestinal inflammation characteristics caused by purinergic receptor 
activation [23]. Recently, inhibition or genetic ablation of Cx43 in EGCs prevented 
inflammation-induced neuronal death [24]. This is interesting because it shows that 
ATP released by EGCs, through Cx43 hemichannels, is involved in both inflamma-
tion and motility [21], as mentioned above.
It is possible that Cx43 expression in EGCs is also related to regulation of the 
intestinal epithelium barrier (IEB). Animals with ablated Cx43 in EGCs also 
exhibited an increased fluid content in stools [21]; this may imply a role of Cx43 in 
regulating the IEB, since EGCs have protective effects on enterocytes. A co-culture 
study showed that EGCs induced in enterocytes an increase in transcription of 
genes involved in cell-to-cell and cell-to-matrix adhesion and also an increase in cell 
adhesion [25]. Some of the glia-derived factors, for example, ATP and prostaglan-
dins, could be released through the Cx43 hemichannels [26]. The other effects may 
come from cell-to-cell contact. EGCs and enterocytes express Cx43 [27], so they 
may perhaps be joined by Cx43 gap junctions. In fact, the membrane potential of 
differentiating enterocytes becomes more positive exclusively when they migrate 
away from the crypt-villous junction [28], possibly due to gap junctions with EGCs 
(they have higher membrane potential) in this region [29].
In addition to the Cx43 hemichannels, EGCs also have sodium, potassium, and 
aquaporin-4 channels, whose presence and subtypes vary among their subtypes. 
Aquaporin channels, for example, are expressed in EGCs within the plexus, but not 
in extraganglionic EGCs [22].
Even in autism, it has been speculated that inadequate Cx43 expression in EGC 
could affect GI motility, which is in fact altered in some patients. Some monogenetic 
autism spectrum disorders are caused by mutations in genes that encode transcrip-
tional or epigenetic factors, for example, methylCpG2-binding protein (MeCP2) in 
Rett syndrome or TCF4 in Pitt-Hopkins syndrome. These mutations could affect the 
transcription machinery required for proper expression of Cx43 in EGCs [30].
Thus, EGCs act largely through the release of different molecules, which can 
happen through the Cx43 hemichannels.
4.  Functions of EGCs in gut homeostasis: released factors by EGCs 
play a role in intestinal epithelial barrier, neurotransmission, and 
gliotransmission
As already mentioned, EGCs are located throughout intestinal layers and 
interact with different cell types within the gut. Thus, this cell type is expected 
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to play a number of important roles in the coordination of gut functions. In fact, 
studies using genetic tools to abrogate GFAP expressing cells resulted in disruption 
in epithelial integrity, extensive intestinal necrosis, and inflammation, followed by 
degeneration of enteric neurons [31, 32], evidencing the importance of EGCs for 
intestinal homeostasis.
EGCs exert their function through the release of important molecules. In the 
intestine, glial-derived neurotrophic factor (GDNF) is released by EGCs and acts 
as an anti-apoptotic factor to epithelial cells, neurons, and EGCs [33–36]. GDNF 
inhibits epithelial cell apoptosis by the activation of GFRα1–GFRα3 receptors and 
RET co-receptor and the activation of mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol-3-kinase/serine–threonine kinase (PI3K/AKT) signaling 
pathways [37, 38]. GDNF also inhibits apoptosis of EGCs in an autocrine manner 
[34]. Mu opioid receptor activation by morphine in EGCs decreases their GDNF 
synthesis, with consequent IEB disruption [39]. Moreover, GDNF has been shown 
to increase the integrity of the IEB via ZO-1 upregulation [38].
Among neuroactive molecules, ATP is the most well-characterized molecule 
released from EGCs. ATP is released through the opening of Cx 43 hemichannels 
[21, 40]. More specifically, the released ATP modifies adjacent glia, triggering intercel-
lular Ca2+ waves and influencing adjacent neurons. The ATP released by EGCs may 
induce neuronal cell death, as discussed above (topic 2). Nitric oxide (NO), a key inhibi-
tory neurotransmitter in the ENS and a factor that drives oxidative stress in disease, is 
also produced by EGCs [41, 42]. This molecule is produced by the enzyme inducible 
nitric oxide synthase (iNOS). Under pathological stimuli, EGCs express iNOS and 
produce large amounts of NO, which may be protective or deleterious depending on the 
circumstances. Some evidence, however, suggest that EGCs may constitutively express 
iNOS and that NO plays a physiological role by modulating epithelial ion transport [41].
The data above have suggested that EGCs play an essential role in neuronal sup-
port and neurotransmission. Indeed, EGCs actively participate in neurotransmis-
sion. Intraganglionic EGCs provide enteric neurons with essential precursors for the 
synthesis of neurotransmitters such as NO [43, 44], glutamate, and γ-aminobutyric 
acid (GABA) [45]. In health, EGCs provide antioxidants, like reduced glutathione 
[46, 47], and growth factors (e.g., GDNF) [48] to neurons. In addition, EGCs sup-
port neurotransmission by regulating the bioavailability of neuroactive substances 
in the extracellular environment. EGC enzymes are essential for the removal of 
neuroactive compounds surrounding enteric neurons. Moreover, glial potassium 
channels maintain neurotransmission and prevent the death of excitotoxic neurons 
by regulating and buffering potassium [13, 49].
A poorly understood question is how EGCs interpret and process the signals they 
receive from enteric neurons to eventually play their presumptive roles in neurons 
and GI function.
Little is known about EGCs activating ligands, but the Ca2+ transients probably 
trigger different modes of gliotransmission, such as Ca2+−dependent exocytosis or 
factor release through the Cx43 hemichannels [50].
Boesmans et al. [51] demonstrated that enteric neurons can communicate with 
adjacent EGCs, releasing purines through their panexin channels. In fact, ATP 
and purines are the most ubiquitous signaling molecules involved in the enteric 
transmission of neurons to glia in vitro [52, 53] and in situ [21, 23, 54–56], but EGCs 
also have other receptors that allow glia to initiate responses to neurotransmit-
ters released by neurons and other neuroactive substances, including receptors to 
norepinephrine, glutamate, thrombin, lipid signaling molecules, serotonin, brady-
kinin, histamine, and endothelin [22].
As mentioned before, it is already known that in vitro propagation of Ca2+ 
responses between EGCs depends on ATP release through hemichannels [40]. And 
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later it was seen that substances released by Cx43 hemichannels mediate intercel-
lular communication between EGCs [21].
How other populations of EGCs outside the enteric ganglia interact with enteric 
neurons is currently unknown.
5. EGC plasticity
The ENS has a significant ability to adapt to microenvironmental influences 
throughout life, either by inflammatory bowel diseases or by changes in eating 
habits [57]. The mechanisms of cellular communication involved in the plasticity of 
EGCs are not yet fully understood. Understanding how EGCs act and especially how 
they perform the role of progenitor cell and differentiate into neuron is of para-
mount importance for a better understanding of how the ENS performs its complex 
functions.
It has already been shown that numerous neural crest-derived stem cells are 
found in different locations in the adult organism, including the intestine [58]. 
When isolated by flow cytometry for p75 markers [59] or integrin-α2 [60], or also 
through dissociation for in vitro cultivation of neurospheres [61, 62], EGCs can 
give rise to a large number of other cells including glial cells, neurons, and even 
myofibroblasts. Following transplantation of these cells into intestinal explants, 
EGCs differentiate into glial and neuronal cells [61, 63]. These data underscore the 
plastic potential of EGCs that, when transplanted into the CNS, are able to func-
tion as oligodendrocytes and astrocytes [26]. It is noteworthy that under different 
physiological conditions and after injury [60], EGCs proliferate and differentiate 
into neuron only upon specific injury situations [64, 65]. Liu and colleagues have 
shown that it is possible to induce neurogenesis in the myenteric plexus in vivo by 
activating the serotonin receptor upon administration of the 5-hydroxytryptamine 
4 (5-HT 4) agonist [66]. Indeed, other studies in postnatal bowel suggest that 
serotonin also promotes ENS repair and neurogenesis via 5-HT4 receptor [67, 68]. 
Moreover, studies have shown that mouse and human EGCs undergo neurogenesis 
after colitis [65, 69].
Under chemical injury with benzalkonium chloride detergent (BAC), it was pos-
sible to observe neurogenesis in vivo. About 3 months after injury, EGCs adjacent 
to the aganglionic area give rise to sox10-positive glial cells expressing the neuronal 
marker HuC/D [64]. It has been proposed that interruption of contact between cells 
(ganglion structure dissociation) may initiate neurogenesis from precursor cells 
expressing EGCs markers (sox10, p75, S100β, GFAP). These studies suggest that tis-
sue dissociation to establish cell culture, as well as that observed in chemical injury, 
could activate the neurogenic potential of EGCs.
A recent work, however, suggested that constitutive neurogenesis occurs in the 
gut [70], contrasting with data obtained by other groups that suggest that intestinal 
neurons are not easily replaced under healthy conditions [71–73]. Moreover, this 
study highlighted a population of nestin-positive adult progenitor cells that give rise 
to new neurons, different from that of GFAP-positive EGCs. These data contrast 
with previous works that had shown nestin and GFAP co-expression by EGCs [60]. 
Furthermore, nestin-expressing intestinal NSCs cells give rise to neurosphere-
derived neurons and glia in vitro. Besides these cells can differentiate into glial, 
neuronal, and mesenchymal lineages in vitro and also generate neurons in vivo [74].
EGCs do not produce extracellular matrix (ECM). However, their processes con-
tact basal lamina proteins including heparan sulfate proteoglycan, type IV collagen, 
and laminin [11, 75, 76]. This suggests that the microenvironment is also a factor 
of great relevance for the function of EGCs and neurons. Recent data demonstrate 
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that EGCs in vitro, in absence of appropriate substrates were stimulated to initiate 
neuronal differentiation. Therefore, it seems that the contact of adult EGCs with 
laminin plays a crucial role in inhibiting their potential for neuronal differentiation 
(Veríssimo et al., 2009).
6. Implications of EGCs in pathological conditions
The importance of the correct neuron-glial communication is evidenced in a 
situation of intestinal inflammation and neurodegeneration, when EGCs act as a 
direct mediator of neuronal cell death.
6.1 EGCs in inflammatory bowel diseases (IBD)
Chronic inflammation in the GI tract can cause important changes in the ENS, 
as demonstrated by several studies in patients with IBD, such as ulcerative colitis 
(UC) and Crohn’s disease (CD)[77, 78]. Both UC and CD are characterized by 
inflammation, which is accompanied by the release of a range of pro-inflammatory 
cytokines, following intestinal dysmotility [79, 80].
An increase in GDNF and GFAP immunolabeling was observed in EGCs in 
inflamed colonic mucosa of patients with UC, CD, and Clostridioides difficile (C. 
difficile) infectious colitis [78]. In addition, S100B upregulation has also been 
identified in a variety of diseases, such as UC [42, 81, 82], celiac disease [83], and 
intestinal mucositis induced by antineoplastic drugs [84, 85]. Increased expression 
of S100B was also found in the intestine of humans with C. difficile infection (CDI), 
in animal model of CDI, and in mouse ileal loop injected with C. difficile toxin A 
(TcdA) (unpublished data).
In intestinal injury, reactive gliosis is a response of EGCs to protect the neuronal 
network during intestinal inflammation [86]. However, depending on the degree 
of inflammation, this event may cause damage to neurons and to EGCs themselves 
due to a deregulated response of these cells to the virulence factors of pathogenic 
bacteria or pro-inflammatory mediators released by immune cells, neurons, or 
EGCs. This dual effects may have an important effect in the instability of the release 
of protective and dangerous factors, such as GDNF, an anti-apoptotic factor, and 
S100B, a pro-inflammatory cytokine, by EGCs [34, 35].
6.1.1 Ulcerative colitis and Crohn’s disease
A strong upregulation in levels of GDNF was reported in the intestinal crypts 
and in the myenteric and submucosal plexuses in patients with CD. In UC, GDNF 
immunoreactivity was reported to be less pronounced than CD. However, no altera-
tion in GFR-1 was evidenced in patients with CD and UC. GFR-1 is a receptor for 
GDNF binding that is predominantly found at the basolateral parts of the human 
colonic epithelium [37].
The EGCs regulate the epithelial barrier function and inflammation through the 
release of S-nitrosoglutathione (GSNO), a potent nitric oxide donor. Interestingly, 
EGCs are the main source of GSNO within the intestine. It has been shown that the 
levels of GSNO are reduced in CD and UC [35]. GSNO regulates the intestinal perme-
ability by stimulating in enterocytes the upregulation of proteins of tight junctions, 
such as occludins and ZO-1, and inhibiting the increase of phosphorylated myosin 
light chain (PMLC), as well as improving the location of these proteins [87].
EGCs from human colonic tissues with Crohn’s disease have reduced 
15-hydroxyeicosatetraenoic (15-HETE) synthesis. As GSNO, 15-HETE controls 
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the paracellular permeability of the IEB by inhibiting adenosine monophosphate-
activated protein kinase (AMPK) and regulating ZO-1 expression [88].
NO, such as tumor necrosis factor-α (TNF-α) and PGE2, plays an important 
role in the pathogenesis of ulcerative colitis and is secreted by EGCs. S100B can induce 
increased NO release, as well as TNF-α and PGE2, by murine and human EGCs via 
S100B/TLR4 [42, 82].
Losses in 61% of the enteric neurons and 38% of the EGCs have been reported during 
ulcerative colitis in human [77]. In fact, activation of EGCs during colitis induced 
by dinitrobenzene sulfonic acid (DNBS) in mice had been shown to be the central 
mechanism in the development of enteric neuropathy, since the gating of glial Cx43 
hemichannels by nitric oxide and subsequent ATP release are required for enteric 
neuron death [24].
6.1.2 Colitis by Clostridioides difficile
C. difficile is an obligate anaerobic, spore-forming Gram-positive bacillus that 
can colonize, germinate, and proliferate in the human gut after antibiotic use [89, 
90]. The incidence of C. difficile infection (CDI) across the world has increased 
with 107,760 admissions per year [91, 92]. The clinical disease ranges from mild 
diarrhea to toxic megacolon, colonic perforation, and death [93].
The major virulence factors of C. difficile are toxins A and B (TcdA and TcdB). 
TcdA and TcdB stimulate the release of a variety of mediators such as interleukin 
(IL)-1β, IL-17, IL-23, TNF-α, CXC motif chemokine ligand 4 (CXCL4), CXCL2, and 
inhibitory macrophage migration factor (MIF) in several cells, such as epithelial 
cells, immune cells, and enteric neurons [94–97]. In contrast to those cells, EGCs 
challenged with TcdA and TcdB do not release detectable levels of IL-1β, interferon-
gamma (INF-γ), and TNF-α [98].
The first studies on changes in the ENS evoked by C. difficile toxins showed 
that TcdA and TcdB excite enteric neurons stimulating the release of substance P 
and vasoactive intestinal peptide (VIP) via noradrenergic transmission inhibition 
and IL-1β pathway, respectively, resulting in neutrophil recruitment and secretory 
diarrhea [99–101].
A recent study demonstrated increased cell population expressing both HuC/D 
and SOX2 in inflamed colonic tissues in patients with CDI [65]. So, these EGCs are 
important for generating new neurons after intestinal injury.
A study of 447 and 444 patients with C. difficile-associated diarrhea acquired in 
the community and hospital, respectively, showed GI dysmotility in these patients 
after 1 year of the last diarrhea episode. Among the dysmotilities are IBD, gastro-
esophageal reflux disease, constipation, and dyspepsia [102]. These dysmotilities 
have been shown to be related to ENS changes. Deregulated activation of EGCs dur-
ing inflammation may alter their regulatory role in motility (discussed in topic 3), 
causing intestinal dysmotility.
It was demonstrated that TcdB stimulates morphological alteration and apoptosis in 
EGCs in vitro [98, 103]. TcdB-induced apoptosis of EGCs involves the NADPH oxidase/
ROS/JNK/caspase-3 signaling pathway independently of the mitochondrial pathway 
[103]. In addition, TcdB induces senescence in EGCs. Cell senescence is characterized 
by alterations in the cell cycle, changes in metabolism, morphology, and gene expres-
sion that together may contribute to persistent inflammation [104].
6.1.3 Inflammation by other causes
It has been demonstrated that EGCs are involved in decreased infection foci and 
IL-8 secretion and in the inhibition of alterations in IEB resistance in infection by 
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Shigella flexneri in rabbit ileal loop model. Similar findings were found in human 
colonic mucosa explants infected with S. flexneri. GSNO released by EGCs showed 
to be a mediator responsible for protecting epithelial cells from S. flexneri-induced 
effects [105].
Giardia duodenalis (also known as G. lamblia or G. intestinalis) is a protozoan 
parasite capable of causing sporadic or epidemic diarrheal illness. Giardia duodena-
lis-induced infection is one of the most common human parasitic diseases world-
wide [106]. Studies have shown a reduction in EGCs from the submucosal plexus of 
the mouse duodenum and jejunum during infection induced by assemblages A and 
B of G. duodenalis. However, only assemblages B of G. duodenalis were observed to 
induce a reduction in those cells from the duodenal myenteric plexus. Surprisingly, 
mice infected with G. duodenalis did not exhibit diarrhea and any alterations in GI 
transit time [107].
Antineoplastic drugs, such as 5-FU, irinotecan, and oxaliplatin, have been cur-
rently used to treat several types of cancer, including breast and colorectal cancer. 
Mucositis and diarrhea are common side effects of these antineoplastic drugs [108]. 
Many cells are stimulated to release inflammatory mediators during intestinal 
mucositis, and persistent GI over-contractility has also been demonstrated, even 
after inflammation has resolved, suggesting that chemotherapy might affect gut 
neuronal and EGC function [109].
During intestinal mucositis induced by oxaliplatin, reduced GFAP and increased 
S100B protein expression were evidenced, as well as reduced co-localization of 
GFAP and S100B in ileal myenteric plexus of mice [110].
In fact, increased S100B release by EGCs has been shown to be a mediator in 
charge of causing neuronal death, as well as reactive gliosis, epithelial damage, 
and inflammatory response (release of IL-6, TNFα, and NO) during 5-FU-induced 
intestinal mucositis via S100B/RAGE/NFκB [84].
As we will deepen later, EGCs can be stimulated by immune cells during intes-
tinal inflammation. A recent study showed that mediators released by mast cells 
cause reactive gliosis and neuronal death together with the intestinal mucositis 
induced by irinotecan [85].
Figure 2 shows a schematic highlighting how EGCs are affected by and partici-
pates on intestinal inflammation.
6.2 EGCs in neurodegenerative diseases
Due to its great interaction with neurons and modulation of neuronal responses, 
it is possible to imagine that EGCs play a central role in neurodegenerative diseases. 
Indeed, the role of EGCs seems to be compromised in many neurodegenerative 
diseases, and this is true for both CNS and ENS.
Enteric neurodegeneration is a common marker for a group of diseases classi-
cally known as enteric neuropathies. The changes found present as alterations in 
enteric smooth cells and/or compromised functioning of the ENS—often impact-
ing in GI motility [111]. The neuropathies chronic intestinal pseudo-obstruction 
(CIPO) and slow transit constipation (STC) are characterized by neurodegenera-
tion affecting the lower GI tract. Moreover, it has already been shown that enteric 
glia is implicated in Parkinson’s disease (PD), and participation in Alzheimer’s 
disease (AD) is speculated [111].
CIPO is a condition characterized by failure of GI motility without apparent 
mechanical lesion [112]. Histological patterns show different classes of the disease 
depending on the cell type involvement (enteric neurons, smooth muscle cells, and 
interstitial cells of Cajal). Enteric neuron degeneration promotes intestinal neuro-
muscular disorders [111, 113]. In chronic idiopathic intestinal pseudo-obstruction 
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(CIIP), EGC infection by JC virus (polyomavirus) has been described suggesting a 
role of enteric glia in this enteric neuropathy [114].
Constipation is a common functional GI disorder characterized by infre-
quent bowel motions and/or incomplete defecation [115]. Studies on the neu-
ronal subtypes involved in the STC pathogenesis are still very uncertain. It was 
pointed that excessive production of NO in the colonic myenteric plexus of STC 
patients would inhibit propulsive contraction. Results about other neurotrans-
mitters as VIP, substance P, and serotonin were contradictory [113]. Besides 
the decrease of enteric neurons and interstitial cells of Cajal, STC also presents 
a significant decrease of EGCs [116], and some discussion has emerged about 
constipation being a neuro-gliopathy [79]. Several reports showed that different 
conditions presenting constipation have a feature: loss of EGCs, and it points to 
a pathophysiological meaning since the EGC directly regulates enteric neurons 
and interstitial cells of Cajal through neurotrophic factors [116, 117] and ATP 
signaling [79, 118].
Figure 2. 
Mediator release by EGCs during intestinal inflammation and their role in the pathogenesis of intestinal 
inflammatory diseases. During intestinal inflammation promoted by ulcerative colitis, Crohn’s disease, colitis 
induced by C. difficile, irinotecan- and 5-FU-induced intestinal mucositis, and enteric glial factors (S100B, 
GDNF and GFAP) are upregulated. EGCs are stimulated to secrete S100B, GDNF, IL-6, ATP, TNF-α, PGE2, 
and NO. In addition, EGCs produce reduced levels of GSNO and 15-HETE during Crohn’s disease, resulting 
in increase of intestinal permeability by ZO-1 downregulation and PMLC upregulation. NO release by EGCs 
promotes Cx43 opening with consequent ATP release by EGCs, resulting in neuronal death in Crohn’s disease. 
In 5-FU-induced intestinal mucositis, S100B released by EGCs via RAGE receptor activation drives reactive 
gliosis, neuronal death, and immune cell activation, whereas mediators released by mast cells induce reactive 
gliosis and neuronal death during irinotecan-induced intestinal mucositis . In ulcerative colitis, S100B activates 
TLR4, resulting in TNFα, PGE2, and NO by EGCs. C. difficile Toxin B (TcdB) induces EGCs apoptosis and 
morphological changes.
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6.2.1 Parkinson’s disease
In the last years, the literature has shown that some pathological conditions, 
such as PD, classically described to compromise the CNS are now recognized as 
multicentric neurodegenerative processes since they affect different systems such as 
the ENS [119–122]. A number of non-motor symptoms in PD have been identified, 
and many of them manifest early, even before the clinical stage of the disease (char-
acterized by emergence of the classic motor features) when the diagnosis can be 
made [123]. They found lesions in autopsies of patients by identifying the presence 
of intraneuronal inclusions called Lewy bodies/neuritis, which are described as pro-
tein agglomerates where α-synuclein is the main constituent. The areas primarily 
affected were olfactory structures, the dorsal motor nucleus of the vagus nerve and 
the ENS [124, 125]. According to Braak’s hypothesis, there could occur a migration 
of the ENS lesion via the vagus nerve to the CNS [124]. Indeed, Lewy neurites are 
detectable in the presymptomatic stage of PD along the autonomic pathways and in 
the GI tract [126]. Besides, analysis of human colon biopsies obtained 2 to 5 years 
before PD onset showed the presence of pathologic α-synuclein in neurodegenera-
tion sites, suggesting that colonic α-synuclein staining can be considered a bio-
marker of premotor PD symptoms [127].
GI symptoms are the most debilitating PD non-motor features and are present 
in almost every patient at some stage of the disorder [124, 128, 129]. The symptoms 
commonly reported by patients are weight loss, dysphagia, decreased frequency of 
intestinal peristalsis, and difficulty in defecation [130]. Recent evidences indicate 
that PD pathological alterations in the gut involve EGCs and probably impairment 
of their critical role in GI physiology. In fact, colonic biopsies of PD patients showed 
an increased expression of GFAP both at the transcript and protein levels [131, 132] 
as well as a reduction in GFAP phosphorylation. These features strongly suggest that 
reactive gliosis may be associated with degenerative diseases [131].
In PD colon biopsies the upregulation of GFAP was accompanied by an increase 
in the expression of pro-inflammatory cytokines, mainly TNF-α, IFN-γ, IL-1β, and 
IL-6 [132]. These data suggest a link between glial dysfunction and enteric inflam-
mation in the colon of PD patients.
Alterations in IEB have been observed in patients and animal models of PD [133, 
134]. Modifications in protein levels and protein distribution that compose the 
barrier (e.g., occludin) were documented [128]. In agreement with this, PD patients 
show fecal biomarkers of inflammation as calprotectin and also increased intestinal 
permeability as alpha-1-antitrypsin [134]. It is known that the IEB is strongly regu-
lated by EGCs [37–39]. Since EGCs is sensitized in PD patients and modulates all 
these processes, it is speculated that IEB could be impaired by altered glial signaling 
which could contribute to the inflammatory process.
Intestinal dysmotility is the symptom that affects directly patient’s quality 
of life and is shared among PD patients. Constipation is the most common non-
motor symptom manifested in both prodromal and clinic phases of PD [135–137]. 
Recently, constipation was included as a criterion for prodromal PD diagnostic, and 
discussion about the validation of constipation as a risk factor for the development 
of PD has been recurrent [138]. As already discussed, impairments in EGCs activity 
produce constipation due to a loss in the neural control of gut motility [21].
However, despite the evidence, there is still no direct demonstration of how 
enteric glia is involved in PD, either in the cause of the disease or its consequences.
In this way, the suggestion that PD could onset in the gut emerges from the 
identification of activated EGCs, local inflammation, impaired IEB, aggregation 
of α-synuclein in neurons, and GI disorders in a window prior to the appearance 
of classic motor deficits. Recently, Seguella et al. suggest that EGCs could be the 
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“missing link” that connects the ENS to the CNS [139]. The authors called attention 
to enteric glial cell-mediated inflammatory response, which could reach the CNS 
by the gut-brain axis and lead to neuronal cell death and disruption of synaptic 
interactions [139, 140]. Thus, EGCs would function as an “entrance door” to 
noxious stimuli from the intestinal lumen that could damage the CNS. However, 
the mechanisms by which the pro-inflammatory glial mediators rise to the CNS still 
remains to be clarified [139].
6.2.2 Alzheimer’s disease
Alzheimer’s disease (AD) is the most common neurodegenerative disorder 
affecting people in the world. The neurodegeneration causes a progressive cognitive 
decline and loss of working memory [141]. Among the non-cognitive symptoms 
of AD are the GI symptoms which point to a role of ENS in AD [142]. In fact, the 
brain biomarker of AD, the extracellular plaques containing β-amyloid, has already 
been described in the intestinal submucosa of patients [143] which is in agreement 
with the expression of amyloid precursor protein in enteric neurons and also EGCs 
[144]. The discussion of the peripheral immune response has been widely debated 
as the pathogenic pattern of AD that contributes to central neurodegeneration 
[145, 146]. In this context, some discussion has been raised about EGC possibly 
acting as a peripheric coordinator of immune differentiation of T cells [139] since 
EGCs express the major histocompatibility complex II and T-cell costimulatory 
molecules [147–149]. As mentioned above, EGCs are able to respond to an inflam-
matory environment contributing to the process, activate enteric neurodegenerative 
mechanisms, and immunomodulate the IEB. All these features could contribute to 
an inflammatory peripheral state and sensibilization of CNS through the blood–
brain barrier [139]. It is still speculative to relate these glial interactions to AD, but 
there are indications of an immunomodulatory relevance of this cell in the GIT, as 
will be discussed again below.
6.3 Interactions between EGCs and the immune system
Recently, insightful and essential findings have shed light in the field of neu-
roimmunology, especially with the development of high solution technological 
approaches to underlie neuroimmune communications. It has been proposed 
that the immune and the nervous systems interact in health and disease and are 
expected to function alongside to promote tissue homeostasis [150]. More specifi-
cally, neuroimmune interactions have been suggested by understanding the relative 
anatomical positioning of cell types and their dynamics within the tissue in homeo-
stasis and response to insults. Moreover, the expression of corresponding ligands 
and receptors by immune and nervous cells, for instance, may determine physiolog-
ical interactions between the two systems. However, efforts to identify mechanisms 
to decipher how immune and neural cells interact in a steady-state environment and 
respond to genetic and epigenetic cues are still a challenge to be addressed.
Because the GI tract is the connection between the external with the internal envi-
ronments of the body, the ENS is continuously exposed and expected to interact with 
the extrinsic (dietary and microbiota-derived metabolites) and intrinsic (immune sys-
tem and stromal cells) environments of the gut. The strategical anatomical positioning 
of ENS and immune cells throughout the GI wall and their physiological features are 
crucial to defeat pathogens and maintain the intestinal homeostasis. Emerging studies 
have identified two distinct types of tissue-resident macrophages within the intestinal 
wall that are closely associated with ENS cells [150]. Lamina propria macrophages 
(LpMs) preferentially display pro-inflammatory phenotype and are the most abundant 
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cell group located just beneath the intestinal epithelium. These cells, together with 
neuronal processes and mucosal EGCs, form tight physical and functional barriers that 
protect the intestines against pathogens, although the mechanisms that underlie those 
interactions are still to be further explored [150].
At the level of the myenteric plexus, muscularis macrophages (MMs) are closely 
associated with neuron cell bodies and fibers and EGCs and present a tissue-pro-
tective phenotype. Similar to microglia in the CNS, MMs can phagocyte neuronal 
debris during homeostasis [70]. Another population of gut self-maintaining mac-
rophages (gMacs) was described to be fundamental for ENS homeostasis since the 
genetic depletion of those macrophages led to a loss of enteric neurons resulting in 
reduced intestinal function [151]. Moreover, enteric neurons and innate lymphoid 
cells type 2 (ILC2) functionally integrate to initiate type 2 immune responses. The 
integration between neuron-ILC2 units is necessary for cytokine production and 
inflammation repair upon worm infection [152, 153].
EGCs also appear to participate in immune responses, but so far, its impact on 
immune cells is still relatively unexplored under homeostasis. However, an excit-
ing study has recently discussed that GDNF secreted by EGCs activates IL-22-
producing ILC3 via Ret signaling [154]. Interestingly, Ret signaling regulates Peyer’s 
patches organogenesis, underlining the prospective role of EGCs in orchestrating 
innate immune functions in the gut [155]. Furthermore, experiments performed 
in the submucosal plexus (SMP) from patients with functional dyspepsia (FD) 
showed that morphological alterations both in EGCs and neurons are due to 
increased numbers of eosinophil and mast cell within ganglionic structures [156]. 
This also suggests that EGCs and the immune system work together to maintain the 
intestinal homeostasis.
It is known that EGCs protect T lymphocytes from cell death by upregulating the 
expression of IL-7 after exposure to pro-inflammatory cytokines such as IL-1β and 
TNFα [157]. Moreover, EGCs were suggested to have immunosuppressive charac-
teristics in CD by inhibiting T-cell proliferation [158]). Nonetheless, the cellular and 
molecular mechanisms that govern the role of EGCs in intestinal pathologies remain 
unclear. EGCs express MHCII [148] that is upregulated under inflammatory condi-
tions [149, 159], conferring an immunological feature to these cells in a pathological 
environment. Moreover, EGCs can secrete and respond to IL-1β, IL-6, and IL-10 
and nitric oxide in vitro, as already mentioned, suggesting another property of 
these cells in the mediation of inflammatory responses [24, 160, 161]. Although, 
it is plausible that EGCs have an important function in modulating neuroimmune 
interactions, understanding their specific contributions to the maintenance of the 
gut homeostasis would be useful to decipher their roles in inflammatory disorders.
This would possibly suggest an immune protective role of EGCs to maintain the 
mucosal barrier. However, those studies failed in showing direct evidence that EGCs 
are necessary for intestinal barrier function. On the other hand, studies in which 
EGCs were disrupted but not entirely ablated did not show any noticeable signs of 
inflammation. In contrast, disruption in EGC homeostasis culminated in changes 
in mucosal function as well as in neurochemical coding, leading to alterations in 
enteric neurons and consequently in motor activity [162–164]. Thus, taken together, 
the immunological roles of EGCs protecting the intestinal environment from dam-
age remain contentious by using genetic tools to ablate/disturb these cells.
7. Conclusion
As we could notice in this chapter, there are still many unexplained aspects of the 
EGCs physiology. Although we have already found interesting studies that show their 
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relation with neurons or alterations in cases of inflammation, the exact mechanisms by 
which EGCs activates neurons to control GI motility are still unknown. Little is known 
about their interaction with the immune system, for example, or their participation 
in neurodegenerative diseases that affect both ENS and CNS. Recently, Seguella et al. 
suggest that EGCs could be the “missing link” that connects the ENS to the CNS [139]. 
EGCs in the context of disease could be an important target for diagnosis and therapy 
of many intestinal and neurological disorders.
Taken together, these evidence show the importance of EGCs for the mainte-
nance of intestinal homeostasis and that disturbance of glial functions could alter 
GI physiology through the modulation of neurotransmission and of the responses 
of the different cellular types or even activation of cellular signals to enter the 
neuronal differentiation processes in specific situations.
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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